Skip to main content

Table 2 Characterization of IFN-γ ELISPOT in response to recombinant Rv1985c and the peptides mixture from ESAT-6 and CFP-10 in TB patients, LTBI and Healthy controls groups:

From: Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls

 

TB (n = 56)

LTBI (n = 20)

HC (n = 30)

Antigens

Mean SFU

± standard error

No. positive1

Sensitivity2 (%)

95% CI (%)

Mean SFU

± standard error

No. positive1

Sensitivity3 (%)

95% CI (%)

Mean SFU

± standard error

No. positive1

Specificity4 (%)

95% CI (%)

Rv1985c

19.3 ± 4.7

40

71.4

57.8 to 82.7

10.0 ± 2.8

11

55

31.1 to 78.9

2.6 ± 1.1

1

96.7

82.8 to 99.9

ESAT-6

66.59 ± 9.35

46

82.16

70.6 to 91.2

37.6 ± 12.0

15

75

54.2 to 95.8

0.77 ± 0.20

0

100.0

88.4 to 100.0

CFP-10

132.8 ± 22.25

38

67.97

54.9 to 80.2

77.9 ± 24.0

15

75

54.2 to 95.8

1.0 ± 0.25

0

100.0

88.4 to 100.0

  1. 1: Positive was defined as SFU greater than or equal to 6 in 2.5 × 105 cells for ESAT-6 and CFP-10, and greater than 4.5 in 2.5 × 105 cells for Rv1985c;
  2. 2: Percentage of responding patients out of all TB patients tested;
  3. 3: Percentage of responding individuals out of all LTBI tested;
  4. 4: Percentage of true-negative healthy controls out of all healthy control individuals tested;
  5. 5: Statistically higher SFU than SFU of Rv1985c by two-tailed paired Mann-Whitney test, p < 0.001;
  6. 6: Statistical significance was determined in respect to sensitivity of Rv1985c by McNemar chi-square test, p = 0.02;
  7. 7: Not significant in respect to sensitivity of Rv1985c by McNemar chi-square test, p = 0.52.